Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2017.1328056
Abstract: ABSTRACT Introduction: Androgen deprivation therapy (ADT) is the mainstay for advanced, hormone-sensitive prostate cancer, and options include surgical castration, luteinizing hormone-releasing hormone (LHRH) agonist, and more recently, gonadotropin releasing hormone (GnRH) antagonist therapy. Our understanding… read more here.
Keywords: hormone; degarelix; releasing hormone; prostate cancer ... See more keywords
Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP+D), and degarelix (D) alone for patients (pts) with biochemically-recurrent prostate cancer (PC) following radical prostatectomy (RP).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.5016
Abstract: 5016Background: Androgen deprivation therapy (ADT) with GnRH analogs does not entirely suppress androgen signaling. AAP + ADT decreases blood and intratumoral testosterone (T) levels by ≥1 log, and... read more here.
Keywords: aap; study abiraterone; arm study; degarelix ... See more keywords
Degarelix vs. leuprorelin for the treatment of prostate cancer in China: A cost-utility analysis
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Public Health"
DOI: 10.3389/fpubh.2022.942800
Abstract: Objective To explore the cost-effectiveness of degarelix acetate for injection (degarelix) compared to leuprorelin in prostate cancer (Pca) castration treatment from Chinese healthcare system perspective. Methods A Markov model, adapted from the one established in… read more here.
Keywords: prostate cancer; cost; analysis; degarelix ... See more keywords
A review of clinical evidence to assess differences in efficacy and safety of luteinizing hormone–releasing hormone (LHRH) agonist (goserelin) and LHRH antagonist (degarelix)
Sign Up to like & getrecommendations! Published in 2022 at "Indian Journal of Cancer"
DOI: 10.4103/ijc.ijc_1415_20
Abstract: Luteinizing hormone–releasing hormone agonist (LHRH-A), goserelin, and antagonist, degarelix, are both indicated for the treatment of advanced prostate cancer (PCa); however, large comparative trials evaluating their efficacy and safety are lacking. In this review, we… read more here.
Keywords: goserelin; luteinizing hormone; degarelix; evidence ... See more keywords